Display options
Cite
Bosly A, Brice P, Humblet Y, et al. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. Nouv Rev Fr Hematol. 1990;32(1):13-6
Bosly, A., Brice, P., Humblet, Y., Doyen, C., Faille, A., Chatelain, B., Franks, C., Gisselbrecht, C., & Symann, M. (1990). Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. Nouvelle revue francaise d'hematologie, 32(1), 13-6.
Bosly, A, et al. "Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease." Nouvelle revue francaise d'hematologie vol. 32,1 (1990): 13-6.
Bosly A, Brice P, Humblet Y, Doyen C, Faille A, Chatelain B, Franks C, Gisselbrecht C, Symann M. Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. Nouv Rev Fr Hematol. 1990;32(1):13-6. PMID: 2349079.
Copy Download .nbib Format: NLM
Share it on

Nouv Rev Fr Hematol. 1990;32(1):13-6.

Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.

Nouvelle revue francaise d'hematologie

A Bosly, P Brice, Y Humblet, C Doyen, A Faille, B Chatelain, C Franks, C Gisselbrecht, M Symann

Affiliations

  1. Université Catholique de Louvain, Laboratoire d'Oncologie et d'Hématologie Expérimentales, Bruxelles, Belgique.

PMID: 2349079

Abstract

Recipients of autologous BMT demonstrate clinically significant immune deficiency, particularly involving the T lymphocytes. While quantitatively the immune system generally returns to normal during the first 3 months, there is a prolonged delay in the recovery of qualitative immune functions. T cell proliferation is impaired immediately after transplantation and slowly recovers over a period of more than 1 year. In addition, a defect has been documented in IL-2 producing cells and may be of major importance in the pathophysiology of this immunodeficiency. However, post-ABMT, PHA-stimulated T cells are TAC+ and are able to respond to exogenous IL-2 in vitro. Very early after ABMT, NK and LAK activities of PBMC normalize but are significantly increased in vitro by IL-2. On this basis, a clinical assessment of rIL-2 administration on the immunological reconstitution of ABMT patients and as consolidation immunotherapy against minimal disease has been initiated in a phase I/II study.

Substances

MeSH terms

Publication Types

LinkOut - more resources